` SMMT (Summit Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

SMMT
vs
S&P 500

Over the past 12 months, SMMT has significantly outperformed S&P 500, delivering a return of 426% compared to the S&P 500's 12% growth.

Stocks Performance
SMMT vs S&P 500

Loading

Performance Gap
SMMT vs S&P 500

Loading
SMMT
S&P 500
Difference

Performance By Year
SMMT vs S&P 500

Loading
SMMT
S&P 500
Add Stock

Competitors Performance
Summit Therapeutics Inc vs Peers

S&P 500
SMMT
ABBV
AMGN
GILD
VRTX
Add Stock

Summit Therapeutics Inc
Glance View

Economic Moat
None
Market Cap
17.7B USD
Industry
Biotechnology

Summit Therapeutics Inc., headquartered in Cambridge, Massachusetts, has carved a niche in the biopharmaceutical landscape with its focus on addressing serious unmet medical needs, primarily through the development of innovative antibiotics and therapies. The company gained significant attention with its efforts to combat antibiotic resistance, a global health threat. Their flagship endeavor, Ridinilazole, is an antibiotic designed to treat C. difficile infections, a prevalent and often severe bacterial infection affecting the gut. The company's proposition is simple yet impactful: develop effective treatments that not only address infections but also potentially reduce recurrence, thereby offering a better therapeutic alternative to existing solutions. Summit's business model is built around advancing their drug pipeline through rigorous clinical trials, securing regulatory approvals, and ultimately achieving commercialization either independently or through strategic partnerships. The partnerships are critical, as they allow Summit to leverage the expertise and market reach of larger pharmaceutical companies. Additionally, these alliances provide financial backing, helping offset the costly nature of drug development. Revenue is primarily driven from these collaborations through milestone payments and eventual product royalties, once their therapies hit the market. This strategic approach allows Summit to focus its resources on research and development while aligning with partners to navigate the complexities of bringing new therapies to patients globally.

SMMT Intrinsic Value
Not Available
Back to Top